Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Two therapeutic areas that sell big in Egypt are antibiotics and NSAIDs. Four of the top 5 selling products of GSK are antibiotics (Augmentin, Duricef, Ceporex and Velosef). Two of them come from BMS.

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Just like our memory and reflexes, the ageing of our immune system can not only cause it to forget how to react to certain ...

GSK is delivering consistent financial performance ... and our technology platforms with a focus on our core therapeutic areas. So with that, I'll now hand over to Luke and Deborah to talk ...

Cullinan Management (CGEM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

GSK confirmed that the program is progressing to Phase 3 ... and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...